DBV Technologies | DBVT - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amarin USD 20.81M 13K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
DBV Technologies USD 136.82M 51.98K 2025-09
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Galectin Therapeutics USD 61K 0 2023-12
Halozyme Therapeutics USD 117.78M 259K 2025-12
Incyte USD 198.46M 2.33M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Sarepta Therapeutics USD 104.96M 196K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
United Therapeutics USD 43.64M 740K 2025-12